Dan Gil, CEO of Pelage Pharmaceuticals, did not expect the rapid attention his company would receive after early data on its lead therapy, PP405, showed promising hair regrowth in patients with androgenetic alopecia. The initial surge of interest began when UCLA published an article about the treatment, which led to national media coverage.
Christina Weng, chief medical officer at Pelage and a practicing dermatologist, noted the heightened public response. “That is not our area of expertise. We’re scientists,” Weng said. “It definitely reflects an increased consumer interest in good science. And I think that story, even without us doing the best job, necessarily, telling it, is taking off on its own.”
PP405 works by activating stem cells in hair follicles to stimulate growth and potentially reverse dormant follicles. According to Gil, this represents a significant step forward for treating pattern hair loss after decades without major advancements.
Weng explained that current approved treatments—minoxidil (Rogaine) and finasteride—offer limited results and often come with side effects such as sexual and mood changes. She said these issues have left many patients seeking unproven remedies: “In that vacuum, desperate patients have indicated that they are willing to spend good money on treatments without any scientific or clinical validation.”
After news of PP405 spread online and through social media communities focused on hair loss, Gil expressed concern about misinformation: “There were people were running around saying, ‘Oh, this thing works in a week,’ or, ‘You’re gonna have a full head of hair in three weeks.’ [It’s] nice that people are excited, but of course, you don’t want there to be unreal expectations either.”
Clinical trial data from June 2025 showed that 31% of male participants with higher levels of hair loss experienced more than a 20% increase in hair density eight weeks after treatment ended. No placebo group members reached this benchmark. These results suggest PP405 may promote faster regrowth compared to existing therapies.
Weng emphasized the difference between PP405 and other options: it stimulates the growth of terminal hairs—thicker and pigmented—as opposed to vellus hairs or "peach fuzz" commonly seen with other treatments.
Investor interest followed quickly after the Phase II trial results. In October 2025, Pelage raised $120 million in Series B funding to support late-stage trials for PP405. Gil stated: “We were very methodical and thoughtful about preparing for the raise.” He added that careful analysis helped set clear expectations for investors regarding efficacy across different patient subgroups.
With strong demand from potential trial participants and sufficient funding secured for upcoming studies and regulatory engagement with the FDA, Pelage plans to advance PP405 toward approval.
Gil also noted how recent success stories in weight-loss drugs have shifted investor focus back toward common conditions like hair loss. He cited industry leaders such as Eli Lilly and Novo Nordisk who have influenced self-pay models for new therapies—a strategy Pelage may consider for PP405 to remain independent rather than seeking acquisition.
“In the past, if you’re going into an area where you need a large sales force, it’s almost prohibitive for a small company to even try to do that,” Gil said. “So it now puts us in a position where that’s an option for us.”
Pelage faces competition from companies like Veradermics—which is developing an oral minoxidil formulation currently in Phase III trials—but sees room for multiple approaches given patient willingness to try several products simultaneously.
“It’s an interesting market as well, that the average consumer is trying three or four different things at a time,” Gil observed.
Weng addressed concerns about increased competition by referencing AbbVie’s Humira experience in psoriasis: “Things didn’t end when Humira became available. And in fact, the more options became available, the larger [the] psoriasis [market] grew.”
Gil concluded by highlighting Pelage’s regenerative medicine approach: “One of the things we’re all so excited about is, this is a regenerative medicine approach...our mechanism is turning stem cells back on to create and regenerate a new hair follicle.”
